secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-073561
Event type: other_material
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Kymera Therapeutics enters $500M at-the-market offering agreement with TD Cowen
-------------------------------------------------------------------------------

- Agreement allows Kymera to sell up to $500M of common stock through TD Cowen at its discretion.
- TD Cowen will receive up to 3.0% commission on gross proceeds from sales under the agreement.
- Kymera terminated its prior Open Market Sale Agreement with Jefferies LLC effective February 26, 2026.
- Kymera filed a resale prospectus for up to 18,819,826 shares and 12,565,253 warrant shares held by certain stockholders.
- The resale filing does not guarantee any sales and Kymera will not receive proceeds from resales by stockholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526073561/0001193125-26-073561-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526073561/d114045d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-073561

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer